Stock Market Reviews

Read and share opinions on BDX (Becton, Dickinson and Company) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

Latest News

• Are Options Traders Betting on a Big Move in BD Stock?
  Dec 24, 2025
• Becton Dickinson (BDX): Evaluating Valuation After New Immunology Partnership with University of Pennsylvania
  Dec 24, 2025
• BD and Penn Institute Ink Collaboration to Advance Immunotherapy
  Dec 22, 2025
• BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry
  Dec 18, 2025
• BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
  Dec 16, 2025
• BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec
  Dec 15, 2025
• Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector
  Dec 11, 2025
• Assessing Becton Dickinson’s (BDX) Valuation After a Year-to-Date Share Price Decline
  Dec 9, 2025
• BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
  Dec 5, 2025

BDX News

• Becton Dickinson Insiders Added US$1.36m Of Stock To Their Holdings
  In the last year, multiple insiders have substantially increased their holdings of Becton, Dickinson and Company...
  Dec 29, 2025
• Hologic's GYN Surgical Segment Looks Poised for Long-Term Growth
  HOLX's GYN Surgical unit gains momentum as the demand for gynecological devices rises globally, driven by innovation, M&A and strong overseas adoption.
  Dec 26, 2025
• Top Stock Reports for AbbVie, Coca-Cola & Chevron
  ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.
  Dec 24, 2025
• Are Options Traders Betting on a Big Move in BD Stock?
  Investors need to pay close attention to BDX stock based on the movements in the options market lately.
  Dec 24, 2025
• Becton Dickinson (BDX): Evaluating Valuation After New Immunology Partnership with University of Pennsylvania
  Becton Dickinson (BDX) just doubled down on immune system science by teaming up with the University of Pennsylvania’s Institute for Immunology and Immune Health to build advanced flow cytometry panels and run a 1,000 patient immune profiling study. See our latest analysis for Becton Dickinson. Those immune profiling and diagnostics wins come as investors are still cautious, with the share price at $195.67 and a year to date share price return of minus 13.61 percent, while the one year total...
  Dec 24, 2025
• BD and Penn Institute Ink Collaboration to Advance Immunotherapy
  BDX teams up with the Penn Institute for Immunology and Immune Health to launch a high-parameter immune profiling study.
  Dec 22, 2025
• Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
  Dec 19, 2025
• Why Becton Dickinson (BDX) is a Top Momentum Stock for the Long-Term
  The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
  Dec 18, 2025
• BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.
  Dec 18, 2025
• Hologic's Genius AI Detection Shows Value by Spotting Missed Cancers
  HOLX's Genius AI Detection flags missed breast cancers, showing promise in improving mammography accuracy and radiologist efficiency.
  Dec 17, 2025
• BD Expands BD MAX With IVDR-Approved VIASURE Tests in Europe
  BDX expands its BD MAX menu in Europe with IVDR-approved respiratory and STI assays, boosting system utility and reinforcing its diagnostics growth strategy.
  Dec 16, 2025
• Is BD’s (BDX) Expanded European Diagnostics Menu Quietly Reshaping Its Competitive Moat?
  BD (Becton, Dickinson and Company) recently expanded its European infectious disease diagnostics portfolio after IVDR certification of two Certest Biotec VIASURE assays for the fully automated BD MAX™ System, covering a wide range of respiratory and sexually transmitted pathogens from streamlined sample workflows. This broadening of the BD MAX™ assay menu deepens BD’s role in high-throughput molecular testing, strengthening its position in hospital and clinical laboratory workflows that rely...
  Dec 16, 2025
• PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
  Appointment Enhances PolyPid’s Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX₁₀₀ New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. “Brooke’s appointment marks an exciting and pivotal moment for P
  Dec 16, 2025
• Is Becton Dickinson Now an Opportunity After Diagnostics Expansion and 2026 Business Separation Plans?
  If you have been wondering whether Becton Dickinson is quietly turning into a value opportunity or just a value trap, you are not alone. This breakdown is designed to give you a clear, no jargon view of where the stock really stands. The share price has bounced 5.6% over the last week and 3.7% over the past month, even though it is still down 11.7% year to date and 10.2% over the last year. This mix often signals shifting expectations around growth and risk. Recent headlines have focused on...
  Dec 16, 2025
• BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe following In Vitro Diagnostic Medical Device Regulation (IVDR) certification of two VIASURE assays developed by Certest Biotec for use on the BD MAX™ System. The addition of these new assays to the BD MAX™ System portfolio enables clinical laboratories to detect a broad range of patho
  Dec 15, 2025
• Becton Dickinson, Bio-Rad, and Thermo Fisher Propel Safety and Automation in Blood Collection Tubes—New Market Report Highlights $7Billion Opportunity
  The blood collection tubes market presents opportunities through innovation in automated systems, advanced materials, and digital traceability to enhance workflow efficiency and compliance. Demand is driven by personalized medicine, diagnostic volume growth, and regulatory needs, with a focus on agility and regional adaptation. Blood Collection Tubes Market Blood Collection Tubes Market Dublin, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The "Blood Collection Tubes Market - Global Forecast 2025-2032" has
  Dec 12, 2025
• Morgan Stanley Highlights Positive Outlook for Becton, Dickinson (BDX) and the MedTech Sector
  Becton, Dickinson and Company (NYSE:BDX) is included among the 15 Best Stocks to Buy for the Long Term. On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, Dickinson and Company (NYSE:BDX) to $210 from $197 and maintained an Overweight rating on the shares. The analyst noted that the company’s […]
  Dec 11, 2025
• Assessing Becton Dickinson’s (BDX) Valuation After a Year-to-Date Share Price Decline
  Becton Dickinson (BDX) has quietly slipped this year, with the stock down about 16% year to date even as annual revenue and net income still show steady growth. This creates a potentially interesting entry point. See our latest analysis for Becton Dickinson. Over the past few months, Becton Dickinson’s share price has bounced around as investors weigh its steady 1 year revenue and net income growth against concerns about valuation and slower device demand. The 1 month share price return has...
  Dec 9, 2025
• 3 Reasons BDX is Risky and 1 Stock to Buy Instead
  BD trades at $194.13 per share and has stayed right on track with the overall market, gaining 12.5% over the last six months. At the same time, the S&P 500 has returned 14.1%.
  Dec 8, 2025
• BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
  BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.
  Dec 5, 2025
• Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions
  HOLX's BCI test gains traction as new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions.
  Dec 4, 2025
• BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and ChemoGLO™, a specialist in hazardous drug detection and decontamination, today announced a strategic collaboration to advance hazardous drug contamination testing in health care settings to improve the safety of health care workers.
  Dec 4, 2025
• There May Be Reason For Hope In Becton Dickinson's (NYSE:BDX) Disappointing Earnings
  The market for Becton, Dickinson and Company's ( NYSE:BDX ) shares didn't move much after it posted weak earnings...
  Dec 3, 2025
• BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new configurations of cell analyzers featuring breakthrough spectral and real-time cell imaging technologies, enabling more labs in academia, pharma and biotech – across scales, needs and budgets – to advance discoveries in immunology, cancer immunotherapy and cell biology.
  Dec 3, 2025
• Is Becton, Dickinson and Company Stock Underperforming the Nasdaq?
  Becton, Dickinson and Company has notably underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.
  Dec 1, 2025
• Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 66% Above Its Share Price
  Key Insights The projected fair value for Becton Dickinson is US$322 based on 2 Stage Free Cash Flow to Equity Becton...
  Nov 28, 2025
• North America Nucleic Acid Amplification Testing Market Analysis Report 2025-2033 - Technological Advances, Rising Diagnostic Demand, and Widespread Applications
  The North American Nucleic Acid Amplification Testing (NAAT) market will reach $7.64 billion by 2033, growing from $3.28 billion in 2024 with a CAGR of 9.87%. Driven by technological advances, rising diagnostic demand, and widespread applications, NAAT proves critical in identifying infectious diseases and genetic mutations. Notably, innovation, automation, and government support bolster the market's expansion. Despite regulatory hurdles and high costs, ongoing collaborations aim to enhance affo
  Nov 28, 2025
• Here's Why Becton Dickinson (BDX) is a Strong Value Stock
  Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
  Nov 25, 2025
• Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
  Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
  Nov 24, 2025
• Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05
  Becton, Dickinson and Company ( NYSE:BDX ) has announced that it will be increasing its dividend from last year's...
  Nov 24, 2025
• BD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Surgiphor™ Surgical Wound Irrigation System in Europe. The system is the first of its kind to receive Conformité Européenne (CE) approval and is now available in select European countries.
  Nov 24, 2025
• How the Story Behind BD Is Evolving After Analyst Downgrades and New Developments
  Becton Dickinson's consensus analyst price target has recently been revised downward, dropping from $206.58 to $201.49 in response to ongoing changes in the company's outlook. This adjustment reflects the evolving mix of optimism and caution among analysts, who are weighing the implications of updated forward guidance and sector challenges. Stay tuned to discover how you can monitor and interpret these shifts in the stock's narrative going forward. Stay updated as the Fair Value for Becton...
  Nov 23, 2025
• How Does Becton Dickinson Stack Up After Regulatory News and Recent Price Swings?
  Ever wondered whether Becton Dickinson is a hidden gem or just another healthcare stalwart that’s not living up to its potential? You’re not alone. Today we’re unpacking its true value so you know exactly where it stands. After dipping 0.2% over the past week but rebounding for a 3.7% gain in the last month, the stock’s recent moves have caught investors’ attention. Its year-to-date return sits at -14.9%. This volatility follows industry-wide shifts in the healthcare sector and recent news...
  Nov 23, 2025
• Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It?
  HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.
  Nov 21, 2025
• What Makes Becton Dickinson (BDX) a Good Long-Term Investment?
  Cullen Capital Management, LLC, operating under the name Schafer Cullen Capital Management, Inc. (SCCM), has released its “SCCM Value Equity Strategy” third-quarter investor letter. A copy of the letter can be downloaded here. The US equity market continued the rally in the third quarter, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. […]
  Nov 19, 2025
• 3 Healthcare Stocks We Approach with Caution
  From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 7.5% has lagged the S&P 500’s 13% climb.
  Nov 18, 2025
• BD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the Conformité Européenne (CE) Marked BD Onclarity™ HPV Assay for the BD COR™ System and the BD Viper™ LT System have been accepted for the World Health Organization (WHO) list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical cancer screening tools in low- and middle-income countries.
  Nov 17, 2025
• Here’s Hinde Group’s Investment Thesis for Becton, Dickinson and Company (BDX)
  Hinde Group, an investment management company, has released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 14.37% (gross) and 13.93% (net) compared to 8.12% for the S&P 500 Total Return. The YTD return was 36.44% (gross) and 34.91% (Net) compared to 14.83% for the Index. The […]
  Nov 17, 2025
• BD Appoints Robert Huffines and Jacqueline Wright to Board of Directors
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Robert "Robbie" Huffines and Jacqueline "Jacky" Wright to its board of directors, effective Dec. 1, 2025.
  Nov 17, 2025
• Aristotle Atlantic’s Core Equity Strategy Sold Becton, Dickinson and Company (BDX) Due to Recent Earnings Weakness
  Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor letter. The letter highlighted the market review, quarterly performance, and attribution analysis. A copy of the letter can be downloaded here. In the quarter, the US equity market rallied, with the S&P 500 Index reaching 8.12%. Bonds also finished higher in […]
  Nov 17, 2025
• Will BD’s (BDX) Push Into At-Home Care and Interoperability Redefine Its Competitive Edge?
  In recent days, Becton Dickinson (BD) introduced the PureWick™ Portable Collection System, an at-home, battery-powered urine management device for wheelchair users, and saw Duncan Regional Hospital become the first U.S. facility to implement BD Alaris™ EMR Infusion Interoperability with the MEDITECH electronic health record system. These developments expand BD’s reach into direct-to-consumer care and strengthen its market-leading interoperability capabilities in infusion safety, positioning...
  Nov 15, 2025
• Becton Dickinson (BDX): Evaluating Valuation Potential Following Recent Share Price Rebound
  Becton Dickinson (BDX) shares have shown relatively little movement in the past week, edging up about 8%. Despite steady revenue and earnings growth over the past year, longer-term returns remain modest compared to market benchmarks. See our latest analysis for Becton Dickinson. BDX’s strong 7-day share price return of 8.6% stands out against a backdrop of long-term underperformance. Total shareholder returns remain in negative territory over the past one, three, and five years. While the...
  Nov 15, 2025
• embecta Announces Major New Commitment to Direct Relief on World Diabetes Day
  Expanded Partnership Will Increase Access to Diabetes Care for Communities Across the U.S. and Globally SANTA BARBARA, CA / ACCESS Newswire / November 14, 2025 / On World Diabetes Day, embecta Corp. (NASDAQ:EMBC), the largest manufacturer of insulin ...
  Nov 14, 2025
• BD’s Q3 Earnings Call: Our Top 5 Analyst Questions
  BD’s third quarter results were broadly in line with Wall Street expectations, reflecting resilience across most of its product portfolio even as certain market headwinds emerged. Management credited strong demand in Interventional, Biologics, and Advanced Patient Monitoring segments for supporting organic growth, while acknowledging that vaccine demand and subdued research funding weighed on parts of the business. CEO Thomas Polen highlighted the sequential acceleration in organic growth and po
  Nov 13, 2025
• Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings
  Soft earnings didn't appear to concern Becton, Dickinson and Company's ( NYSE:BDX ) shareholders over the last week. We...
  Nov 13, 2025
• BDX Unveils Portable PureWick System for On-the-Go Incontinence Care
  BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.
  Nov 13, 2025
• Duncan Regional Hospital Becomes First in U.S. to Implement BD Alaris™ EMR Infusion Interoperability with MEDITECH
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Duncan Regional Hospital ("DRH Health") has become the first hospital in the United States to implement BD Alaris™ EMR (Electronic Medical Record) Interoperability with the MEDITECH electronic health record (EHR), marking a significant advancement in patient safety, workflow efficiency and clinician support.
  Nov 13, 2025
• First Pacific Advisors' Strategic Moves: Becton Dickinson & Co Takes Center Stage
  Exploring the Latest 13F Filing for Q3 2025
  Nov 13, 2025
• What Are Wall Street Analysts' Target Price for Becton, Dickinson and Company Stock?
  Although Becton, Dickinson and Company has underperformed the broader market over the past year, Wall Street analysts maintain a measured optimism about the company’s long-term outlook.
  Nov 13, 2025
• Unpacking Q3 Earnings: BD (NYSE:BDX) In The Context Of Other Surgical Equipment & Consumables - Diversified Stocks
  Wrapping up Q3 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - diversified stocks, including BD (NYSE:BDX) and its peers.
  Nov 12, 2025
• BD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go
  BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, introduces the PureWick™ Portable Collection System, a discreet, first-of-its-kind, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home.
  Nov 12, 2025
• Pfizer, Amneal, Jazz Pharmaceuticals, BD, and DaVita Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
  Nov 11, 2025
• Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $1.05
  The board of Becton, Dickinson and Company ( NYSE:BDX ) has announced that the dividend on 31st of December will be...
  Nov 9, 2025
• BDX Q3 Deep Dive: Portfolio Resilience and Strategic Actions Amid Macro Headwinds
  Medical technology company Becton, Dickinson and Company (NYSE:BDX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 8.3% year on year to $5.89 billion. Its non-GAAP profit of $3.96 per share was 1.2% above analysts’ consensus estimates.
  Nov 7, 2025
• Becton Dickinson Insiders Added US$1.36m Of Stock To Their Holdings
  Quite a few insiders have dramatically grown their holdings in Becton, Dickinson and Company ( NYSE:BDX ) over the past...
  Nov 7, 2025
• Following the Narrative for BD Amid Executive Changes and Updated Analyst Outlooks
  Becton Dickinson’s stock narrative has shifted slightly, with the Fair Value Estimate declining modestly from $208 to approximately $206.58 as analysts take a more cautious stance on upcoming earnings. In addition, the discount rate has risen from 8.17% to 8.57%, suggesting the market is now pricing in a higher level of risk. Stay tuned to discover what is driving these changes and how you can continue tracking this evolving story. Stay updated as the Fair Value for Becton Dickinson shifts by...
  Nov 7, 2025
• Hologic's Breast Health Rebounds, Takes Spotlight in Buyout Deal
  After a strong Q4 rebound, HOLX's Breast Health takes center stage in the company's upcoming private equity takeover.
  Nov 7, 2025
• 3 Undervalued Dividend Kings to Buy on the Dip Right Now
  Dividend Kings are stocks that’ve had their dividend payouts raised for 50 consecutive years or more, such as Target (NYSE:TGT), Becton Dickinson (NYSE:BDX), and Hormel Foods (NYSE:HRL). That is an exceptional feat that the vast majority of stocks in the market cannot match. For a business to pay rising dividends to its shareholders for half ... 3 Undervalued Dividend Kings to Buy on the Dip Right Now
  Nov 6, 2025

BDX Reviews

• AlphaHawk

  Dec 30, 2025

  $BDX Stitching the future of health, always in demand!

  Buy

• ProfitVortex

  Dec 30, 2025

  $BDX They say needles and forks don’t mix, but this company must have never heard that while saving lives and making dinner parties happen!

  Buy

• PortfolioFreak

  Dec 29, 2025

  $BDX This company is grappling with increasing scrutiny and competition in the medical field. Are they nimble enough to stay ahead, or are they on the brink of a downturn?

  Sell

• MarketDrift

  Dec 29, 2025

  $BDX Solid vibes here, steady like your favorite classic track!

  Buy

• EquityAssault

  Dec 28, 2025

  $BDX A healthcare giant that's lost its footing.

  Sell

• MarketGlitch

  Dec 28, 2025

  $BDX Facing regulatory challenges and market pressures, this firm's ability to innovate is under constant scrutiny. Can they maintain their solid reputation against evolving industry standards?

  Sell

• StockSpecter

  Dec 28, 2025

  $BDX Are they even trying, or just collecting checks?

  Sell

• ShortKingston

  Dec 27, 2025

  $BDX This company is like the MacGyver of healthcare—fixing problems with just a bit of creativity and some serious know-how!

  Buy

• ShortAndProud

  Dec 26, 2025

  $BDX Healthcare's where the cash is, but watch for shake-ups!

  Sell

• CapitalCarnage

  Dec 26, 2025

  $BDX Sticking needles in a haystack of problems.

  Sell

• ChartNomad

  Dec 26, 2025

  $BDX With healthcare demand skyrocketing, this giant is under constant pressure to deliver and innovate. Any misstep could send ripples through the market, making every decision feel like a ticking time bomb.

  Sell

• DiamondHands

  Dec 26, 2025

  $BDX Investing here feels like having a first-aid kit in your wallet—always good to have, even if you hope you never need it!

  Buy

• GainMachine

  Dec 25, 2025

  $BDX This stock is like the guy who always shows up with snacks to the party – you just know it’ll come through when you need it!

  Buy

• FUDCrusher

  Dec 25, 2025

  $BDX Solid player in healthcare, makin' moves, trust the hustle!

  Buy

• HODLzilla

  Dec 25, 2025

  $BDX Legit player in the health game, always on the grind.

  Buy

• TheAlphaDagger

  Dec 24, 2025

  $BDX This giant is navigating a tricky landscape, and if they falter, it could send shockwaves through the industry. Definitely a nail-biter here!

  Sell

• QuantQuest

  Dec 23, 2025

  $BDX This company is out here like a superhero, saving lives one needle at a time! Get ready for some serious medical magic.

  Buy

• YOLOTrader69

  Dec 23, 2025

  $BDX Got the goods for keeping folks healthy, can't go wrong with that hustle!

  Buy

• ProfitGremlin

  Dec 23, 2025

  $BDX Big name, steady flow, but not the hottest right now.

  Sell

• CashCraze

  Dec 23, 2025

  $BDX With a strong portfolio of medical technologies and a commitment to innovation, this firm remains a key player in the healthcare sector. Its ongoing investment in research and development reflects a dedication to improving patient outcomes.

  Buy

• PixelBroker

  Dec 22, 2025

  $BDX This company is like the ninja of healthcare, silently making sure everyone is well equipped. Healthcare warriors, unite!

  Buy

• FinTechFrost

  Dec 22, 2025

  $BDX This company is like the unsung hero of healthcare—always in the background, but without them, things might get a little messy!

  Buy

• StonkDestroyer

  Dec 21, 2025

  $BDX A medical company that feels like it's lost in the shuffle.

  Sell

• StockSpecter

  Dec 21, 2025

  $BDX Innovative? More like perpetually stuck in the status quo.

  Sell

• TickerTakedown

  Dec 21, 2025

  $BDX If needles were gold, this company would be rich! But let’s hope their stocks don’t give me a prickly feeling!

  Sell

• CodeTrader

  Dec 20, 2025

  $BDX The tension is thick with this stock. Recent developments have left investors biting their nails, wondering if it can navigate through the turmoil or if it's destined for a downturn.

  Sell

• TrendScript

  Dec 20, 2025

  $BDX With a strong presence in the healthcare sector, this organization continually enhances its product portfolio through research and development. Its commitment to quality and innovation in medical technology underscores its reputation as a trusted provider.

  Buy

• FiscalEngine

  Dec 20, 2025

  $BDX Renowned for its innovative medical technology, this organization remains at the forefront of advancements in healthcare solutions, showcasing strong potential for future growth.

  Buy

• GainMachine

  Dec 19, 2025

  $BDX This company is like the superhero of healthcare, making needles and syringes that don’t ask for cape-wearing. Who knew medical supplies could have a sense of humor?

  Buy

• ShortSavage

  Dec 19, 2025

  $BDX In the medical field, one misstep can cost a fortune! With all these regulations and fierce competition, the pressure is immense. Keep your eyes peeled!

  Sell

• DividendHunter

  Dec 19, 2025

  $BDX A giant in the industry, but not exactly a rock star.

  Sell

• MarketGlitch

  Dec 18, 2025

  $BDX In the healthcare space, this giant faces fierce competition and innovation demands! Can they keep their edge or are they slipping? The tension is palpable, and every move counts!

  Buy

• CapitalCreep

  Dec 17, 2025

  $BDX Innovation? More like stagnation with a side of mediocrity.

  Sell

• StonkDestroyer

  Dec 17, 2025

  $BDX Still waiting for this giant to innovate – hurry up!

  Sell

• EarningsSync

  Dec 17, 2025

  $BDX As the global health landscape evolves, will this company adapt swiftly enough to maintain its foothold in the competitive medical device arena?

  Buy

• ChartCrusher

  Dec 16, 2025

  $BDX Medical devices from the stone age won't win any awards.

  Sell

• QuantKnight

  Dec 16, 2025

  $BDX The healthcare sector never sleeps, and every advancement brings both opportunity and challenge. Will this entity adapt quickly enough to outpace its rivals and satisfy urgent needs?

  Buy

• TickerTyrant

  Dec 16, 2025

  $BDX This one’s just cruising on past accolades.

  Sell

• RiskWraith

  Dec 16, 2025

  $BDX With demand for medical supplies surging, can this company keep pace? Innovations are crucial, but competition looms large. Every quarter counts!

  Buy

• TradeNova

  Dec 16, 2025

  $BDX Sticking needles in some serious profits, no doubt!

  Buy

• TheChartCode

  Dec 15, 2025

  $BDX They're like the superheroes of the medical world – capes not included, but definitely saving the day!

  Buy

• FinTechNomad

  Dec 15, 2025

  $BDX Upside breakout probability increasing.

  Buy

• TheTradingVerse

  Dec 14, 2025

  $BDX Known for its medical technologies, this company has consistently pushed the envelope in healthcare innovation. Its focus on improving patient outcomes positions it favorably amidst growing global health demands.

  Buy

• PnLPhantom

  Dec 14, 2025

  $BDX In a landscape where medical devices are under scrutiny, this giant is feeling the heat. Will they navigate regulatory challenges successfully or face setbacks?

  Sell

• BullishShade

  Dec 14, 2025

  $BDX Bulls carving out higher structure.

  Buy

• QuantKnight

  Dec 14, 2025

  $BDX In the always-evolving healthcare landscape, staying relevant is a Herculean task. Will this company innovate enough to thrive or fade into obscurity? The pressure never lets up!

  Buy

• VolatilityCore

  Dec 13, 2025

  $BDX With a strong reputation for delivering high-quality medical devices and a commitment to innovation, this company is well-equipped to address evolving healthcare needs. Their diverse product range and strategic partnerships enhance their market position.

  Buy

• TickerTakedown

  Dec 13, 2025

  $BDX This company is like the quiet kid in class—smart and always doing the right thing, but can they finally get the spotlight?

  Buy

• GammaSlayer

  Dec 13, 2025

  $BDX Momentum stacking bullishly.

  Buy

• FiscalFrost

  Dec 13, 2025

  $BDX Long opportunities everywhere.

  Buy

• CapitalCreep

  Dec 13, 2025

  $BDX Nothing says innovation like a company stuck in the past.

  Sell

• ManiaBroker

  Dec 12, 2025

  $BDX If needles could talk, this company would have them saying 'We make healthcare slightly less scary!'

  Sell

• LiquidLegend

  Dec 12, 2025

  $BDX They make stuff that helps people feel better, which is basically superhero stuff – capes not included!

  Buy

• TradeHex

  Dec 12, 2025

  $BDX High-volume bounce suggests institutional activity.

  Buy

• CashWraith

  Dec 12, 2025

  $BDX Unfavorable macro sentiment.

  Sell

• FUDCrusher

  Dec 12, 2025

  $BDX Volume confirming bullish breakout potential.

  Buy

• BullishMyth

  Dec 11, 2025

  $BDX With strong fundamentals and a solid track record in healthcare, this company is navigating the complexities of the market like a pro. But is it enough to withstand the pressure?

  Buy

• ChartCrusher

  Dec 11, 2025

  $BDX All metrics pointing bullish.

  Buy

• LiquidityLord

  Dec 11, 2025

  $BDX Market participants offloading positions.

  Sell

• ManiaBroker

  Dec 11, 2025

  $BDX Sellers draining momentum.

  Sell

• TickerTrickster

  Dec 11, 2025

  $BDX Buyers stepping up aggressively.

  Buy

• BullRaid

  Dec 10, 2025

  $BDX A giant in a field of mediocrity; good luck standing out.

  Sell

• BuyLowBro

  Dec 10, 2025

  $BDX Their products are the best thing since sliced bread – if sliced bread could help you avoid going to the hospital!

  Buy

• PixelBroker

  Dec 9, 2025

  $BDX This company's equipment is so sharp, they probably have to keep it in a special cabinet. Just don’t get too close!

  Buy

• ProfitGremlin

  Dec 9, 2025

  $BDX Market signaling deeper correction.

  Sell

• TradeReckoner

  Dec 9, 2025

  $BDX They always seem to have a needle in the wrong haystack.

  Sell

• MarketReaper

  Dec 8, 2025

  $BDX This company is the Swiss Army knife of healthcare—always ready with the right tool for any situation!

  Buy

• TheEquityEdge

  Dec 7, 2025

  $BDX A leader in the medical technology sector, this company is dedicated to developing innovative devices that improve patient outcomes. Its extensive research and development capabilities ensure a steady pipeline of groundbreaking solutions to address healthcare challenges.

  Buy

• TendieTitan

  Dec 6, 2025

  $BDX This stock is basically the high school nerd that ends up being the CEO. You gotta respect that!

  Sell

• WallStreetGrim

  Dec 5, 2025

  $BDX A leader in medical technology, this company is committed to enhancing global health through innovative solutions. Their ongoing investment in research and development bodes well for future growth and market leadership.

  Buy

• LiquidLegend

  Dec 5, 2025

  $BDX If being sharp was an Olympic sport, this company would take home the gold. Just don’t poke yourself on their success!

  Buy

• YieldSlasher

  Dec 4, 2025

  $BDX A relic in an industry that demands innovation, not stagnation.

  Sell

• CapitalCrusher

  Dec 4, 2025

  $BDX This company’s got more needles than my mom’s sewing kit—now that's a sharp investment!

  Buy

• GainSurge

  Dec 4, 2025

  $BDX Buyers not backing down.

  Buy

• HODLWarrior

  Dec 4, 2025

  $BDX Momentum oscillators showing bullish divergence.

  Buy

• HedgeKnight

  Dec 4, 2025

  $BDX Downtrend clearly dominant.

  Sell

• MarketGlitch

  Dec 3, 2025

  $BDX With healthcare constantly evolving, this giant is under the microscope. Market pressures and innovation demands create a high-stakes environment that keeps everyone guessing.

  Sell

• TradingNomad

  Dec 3, 2025

  $BDX Healthcare is a battlefield, and every product launch feels like a high-stakes poker game! With regulatory hurdles and market dynamics at play, can they stay ahead, or will they find themselves in a corner? It’s anyone's guess!

  Sell

• TickerTrickster

  Dec 3, 2025

  $BDX This one's got the tools to make moves in the healthcare hustle!

  Buy

• CashKiller

  Dec 3, 2025

  $BDX Essential equipment, but their growth is painfully slow.

  Sell

• DividendJunkie

  Dec 3, 2025

  $BDX Stuck in the past, while the future moves on.

  Sell

• DigitalDividend

  Dec 2, 2025

  $BDX With medical gear this slick, it’s like being the coolest doctor in town—only without the lab coat!

  Buy

• StockShotz

  Dec 2, 2025

  $BDX This company is all about needles and syringes – I guess you could say they really know how to poke around!

  Sell

• MarginMyth

  Dec 1, 2025

  $BDX In a sea of giants, this one barely makes a ripple.

  Sell

• IndexPredator

  Nov 30, 2025

  $BDX In a critical industry where every innovation can mean life or death, navigating market challenges is crucial. Are they keeping pace, or are they about to fall behind?

  Sell

• CapitalRush

  Nov 30, 2025

  $BDX With a reputation for high-quality medical devices, this company continues to lead in innovation and market share. Its strategic investments in research and development bode well for its future in the healthcare landscape.

  Buy

• ProfitShade

  Nov 30, 2025

  $BDX They’re making moves in healthcare, gotta respect that.

  Buy

• ShortSurge

  Nov 29, 2025

  $BDX With a strong legacy in medical technology, this company continues to innovate in various healthcare sectors. Its commitment to enhancing patient care through advanced solutions showcases its vital role in the evolving medical landscape.

  Buy

• StonkDestroyer

  Nov 29, 2025

  $BDX Once respected, now just coasting on past glory.

  Sell

• BearFighter

  Nov 28, 2025

  $BDX A dinosaur in a fast-paced world of innovation.

  Sell

• MarketNomad

  Nov 28, 2025

  $BDX This giant has lost its step in the medical field.

  Sell

• TheQuantEdge

  Nov 28, 2025

  $BDX With innovations in healthcare technology accelerating, this giant seems poised for a leap! But with great opportunity comes great scrutiny; can they maintain their standards under pressure?

  Buy

• DividendDemon

  Nov 27, 2025

  $BDX They make tools for needles, which is kind of like being the unsung hero of the healthcare world! Just watch out for the pointy end!

  Buy

• PnLPhantom

  Nov 26, 2025

  $BDX Healthcare innovations are exciting, yet the pressure to deliver consistently high-quality products is immense. One misstep could shake everything up!

  Buy

• TradeFrenzy

  Nov 26, 2025

  $BDX This one’s stuck in a medical drama with no happy endings.

  Sell

• MarketSavage

  Nov 26, 2025

  $BDX They might be at the forefront, but watch your step.

  Sell

• YOLOHold

  Nov 26, 2025

  $BDX Solid player in the game, always delivering the goods, can’t go wrong.

  Buy

• PixelBroker

  Nov 26, 2025

  $BDX When you’ve got a company that helps with needles, it’s like they’re the original ‘pun-ch’ line in healthcare! Who needs superpowers when you’ve got syringes?

  Buy

• MarketMatrix

  Nov 26, 2025

  $BDX This company is like the reliable friend who always brings snacks to the party—you can count on it every time!

  Buy

• QuantQuest

  Nov 25, 2025

  $BDX This stock is like a high school overachiever—always has good grades but might be a little too serious for the party!

  Sell

• OptionOutlaw

  Nov 25, 2025

  $BDX Reliability? More like a slow march to mediocrity.

  Sell

• BullishSniper

  Nov 25, 2025

  $BDX This company is like the Swiss army knife of healthcare—if only it could fix my broken heart too. Solid choice!

  Buy

• ManiaBroker

  Nov 24, 2025

  $BDX This company is like the wizard of medical tech – making things happen with needles that are less scary than your prom date!

  Buy

• DiamondHandz

  Nov 24, 2025

  $BDX They got the tools to keep us healthy, making moves in the game!

  Buy

• CryptoCobra

  Nov 23, 2025

  $BDX They're like the responsible adult at a party – keeping everything in check while the rest of us dance dangerously close to trouble!

  Buy

• MarginMeme

  Nov 23, 2025

  $BDX They’re the real deal in healthcare, keepin' it safe and sound!

  Buy

• TradeBlitz

  Nov 23, 2025

  $BDX If this brand were a doctor, it would definitely prescribe a healthy dose of innovation with a side of reliability!

  Buy

• YOLOTrader69

  Nov 22, 2025

  $BDX This company’s like a steady hand in a wild game, always clutch.

  Buy

• CryptoCoyote

  Nov 22, 2025

  $BDX With regulatory pressures mounting, this powerhouse in the healthcare sector is feeling the heat. The stakes are higher than ever, and it’s crucial to monitor their next moves closely.

  Sell

• DividendHunter

  Nov 21, 2025

  $BDX Their products are sharp, but their profits are dull.

  Sell

• RiskVandal

  Nov 21, 2025

  $BDX Sure, they make needles. But do we need more?

  Sell

• AlphaRogue

  Nov 21, 2025

  $BDX This company is like the superhero in the medical world—saving lives one syringe at a time. Capes, not required!

  Buy

• AlphaDecoder

  Nov 20, 2025

  $BDX Renowned for its commitment to innovation in medical technology, this firm consistently delivers impactful solutions that improve healthcare outcomes worldwide.

  Buy

• StockStrider

  Nov 20, 2025

  $BDX This company continues to innovate in the medical technology field, showcasing its commitment to enhancing patient care through cutting-edge solutions. Their robust pipeline and strategic acquisitions position them for sustained growth in a rapidly evolving healthcare landscape.

  Buy

• BuyLowBoi

  Nov 20, 2025

  $BDX Always in the mix, these folks got the healthcare game on lock!

  Buy

• CashOverload

  Nov 19, 2025

  $BDX Innovation? More like stagnation in a lab coat.

  Sell

• WallStreetWolf

  Nov 19, 2025

  $BDX This stock has more versatility than a Swiss Army knife. It’s a solid choice for all your investing needs!

  Buy

• GainMachine

  Nov 18, 2025

  $BDX The ultimate toolkit for your medical needs! Just don’t try to fix your own toys with it!

  Buy

• ShortCircuit

  Nov 17, 2025

  $BDX This one is just a fancy way to sell needles.

  Sell

• YieldHunter

  Nov 17, 2025

  $BDX With a strong reputation for innovation in medical technology, this company continues to expand its product line, focusing on improving patient outcomes and healthcare efficiency. Their commitment to research and development positions them well in a growing industry.

  Buy

• BearishBoi

  Nov 17, 2025

  $BDX If this company was a needle, it’d be the only one in a haystack that actually wants to poke you. Talk about pointy investments!

  Buy

• BullishMyth

  Nov 16, 2025

  $BDX Health care innovation is a double-edged sword, and the pressure to deliver results is immense! Do they have what it takes to thrive when competition is fierce? It's a test of endurance!

  Buy

• LiquidLegend

  Nov 15, 2025

  $BDX Making needles and syringes cooler than your average pop star! Who knew health tech could rock this hard?

  Buy

• HODLzilla

  Nov 15, 2025

  $BDX Stable and strong, like your favorite pair of kicks.

  Buy

• FOMOKing

  Nov 15, 2025

  $BDX Medical gear is steady, they’re always in demand, ya feel?

  Buy

• Stonks4Days

  Nov 14, 2025

  $BDX Steady hands in healthcare, they’re always in the mix.

  Sell

• Stonks4Days

  Nov 14, 2025

  $BDX They got that steady grind, always in the health hustle!

  Buy

• QuantumBroker

  Nov 14, 2025

  $BDX In the healthcare sector, every innovation could make or break the future! With fierce competitors lurking around every corner, the stress of maintaining a leading edge is palpable!

  Sell

• StonkRider

  Nov 13, 2025

  $BDX This company continues to innovate in the medical technology space, ensuring vital healthcare needs are met. With advancements in its product offerings, it is well-positioned to adapt to changing market demands and improve patient outcomes.

  Buy

• BuyLowBro

  Nov 13, 2025

  $BDX If medical supplies were superheroes, this stock would definitely be wearing a cape—saving the day, one needle at a time!

  Buy

• PortfolioGremlin

  Nov 13, 2025

  $BDX Sharp moves in the med game, always on point with innovation!

  Buy

• TheMemeInvestor

  Nov 13, 2025

  $BDX Medical gear's got the streets buzzin', deliverin' the goods without a hitch!

  Buy

• CapitalCreep

  Nov 12, 2025

  $BDX This one’s as essential as a broken pencil.

  Sell

• TradeRebel

  Nov 11, 2025

  $BDX Innovation is key in the medical sector, yet with challenges in supply chains, will they adapt fast enough to keep up with competition?

  Sell

• TendieTitan

  Nov 11, 2025

  $BDX Imagine if your doctor had a superhero cape—this company is saving lives without the spandex!

  Buy

• RiskAssassin

  Nov 11, 2025

  $BDX A giant in the industry, yet can it sustain its dominance amid rising challengers? The tension is mounting!

  Sell

• QuantRift

  Nov 10, 2025

  $BDX A leader in medical technology, the company continues to excel in creating solutions that enhance patient outcomes. Its steady growth trajectory reflects a strong commitment to innovation and quality.

  Buy

• MoneyMage

  Nov 10, 2025

  $BDX Medical supplies? More like overpriced band-aids for your wallet.

  Sell

• TrendScript

  Nov 9, 2025

  $BDX A leader in the medical technology sector, this company is at the forefront of healthcare innovation. Its robust product offerings and dedication to research and development point to a strong future in improving health outcomes.

  Buy

• CapitalFrame

  Nov 8, 2025

  $BDX This leader in medical technology consistently innovates to improve patient outcomes. Its extensive product range and commitment to quality make it a reliable choice in the ever-evolving healthcare landscape.

  Buy

• OptionNomad

  Nov 7, 2025

  $BDX In a world where healthcare innovations race against time, this company stands at the forefront, but can it keep up with the relentless pressure to deliver groundbreaking solutions? Every moment counts, and investors are nervously watching the clock tick down.

  Buy

• StonkDestroyer

  Nov 7, 2025

  $BDX Just another healthcare giant pretending to innovate while they count their cash.

  Sell

• CandleBinary

  Nov 5, 2025

  $BDX If charts could talk, this one would say, 'Let's ride!'.

  Buy

• QuantQuest

  Nov 3, 2025

  $BDX mode hard watching patience grind feels tax patience patience rough energy dead whispers volume loud wild

  Sell

• VolatilityStrike

  Nov 3, 2025

  $BDX This is what hopium looks like in real time. If this.

  Sell

• MarginMeme

  Nov 2, 2025

  $BDX maybe diamond imo tape clear heavy money fast clean go here tape now earnings level-to-level gains here theta mooning go tax tbh gains tbh

  Buy

• GainsJester

  Nov 1, 2025

  $BDX Even my coffee is less jittery than this price action.

  Sell

• FiscalFrost

  Oct 28, 2025

  $BDX This volume deserves a standing ovation. Every breakout feels like a high-five from.

  Buy

• VolatilityStrike

  Oct 25, 2025

  $BDX This move sponsored by caffeine and regret. I'm emotionally diversified but.

  Buy

• DividendVortex

  Oct 16, 2025

  $BDX Traders in disbelief, bulls in paradise. Every breakout feels like a high-five from the.

  Sell

• TradingNomad

  Oct 15, 2025

  $BDX lately hope a is like looks not fire dumpster a strategy

  Sell

• TheTradingVerse

  Oct 11, 2025

  $BDX This chart looks like it just had an energy drink.

  Buy

• MarketDrift

  Oct 6, 2025

  $BDX ath money spike heating heavy hedges keeping hands vibes wild heating clean tape vol heater whispers humming risk heating nasty queued heat fast noise fast theta heavy

  Buy

• TheRiskDealer

  Oct 6, 2025

  $BDX bounce sold I've hope soap instantly strategy is a recoveries seen operas in not gets better every

  Sell

• ProfitGremlin

  Sep 26, 2025

  $BDX Energy in this move is contagious - someone call CNBC.

  Sell

• BullishBard

  Sep 14, 2025

  $BDX If patience was a stock, I'd be rich by now. Can't tell if it's.

  Sell

• StonkSlayer

  Sep 12, 2025

  $BDX theta soon-ish spike talking heavy hard headfake steady today heavy patience weak doom city dive sentiment queued

  Sell

• Stonks4Days

  Sep 5, 2025

  $BDX humming mode theta fast choppy supply candle trend eyes steady doom tape sentiment risk today ouch dumping tape

  Sell

• BearishBoi

  Aug 29, 2025

  $BDX The price action just ghosted resistance again. Even my coffee is less jittery.

  Sell

• RiskVandal

  Aug 23, 2025

  $BDX sauce city patience range noise bagholder macro sauce keeping wild choppy trap stops

  Sell

• TickerFlux

  Aug 18, 2025

  $BDX This rally just cured my Monday blues. Price action so smooth it.

  Buy

• EarningsEcho

  Jun 14, 2025

  $BDX move earnings macro whoa grind now humming go buzzing mooning gains watching buzzing vibes it volume spicy

  Buy

• CapitalNova

  Jun 12, 2025

  $BDX feels broken out hedges macro heavy weak tight mode nasty today mess queued macro fading today weak

  Sell

• LiquidKnight

  Mar 21, 2025

  $BDX no imo lows frankly cliff heavy keeping hard levels out money today charts whispers it vol dead

  Sell

• Stonks4Days

  Feb 18, 2025

  $BDX trend dead liquidity diamond rough trap volume loud tape now heavy frankly ugly whoa wild hands on lower humming

  Sell

• OptionCipher

  Nov 22, 2024

  $BDX sentiment hurts heat levels steady breakout bid fast patience noise queued heat heavy gains on macro strong humming theta bid

  Buy

• ShortSavage

  Oct 7, 2024

  $BDX humming patience breakout clear go soon level-to-level frankly vibes crushing hedges gap

  Buy

• HODLzilla

  Aug 24, 2024

  $BDX smart clear earnings hurts money vol staying beastly range no tight tape wild level-to-level today go dripping rocket hard

  Buy

• ShortKingston

  Jul 19, 2024

  $BDX heavy sentiment ouch smart feels trend level-to-level today macro ouch weak mode

  Sell

• OptionShadow

  Jul 4, 2024

  $BDX money clean trend queued and today volume now strong sentiment heavy steady vibes it and

  Buy

• TradeHex

  Jun 27, 2024

  $BDX bull risk grind heater tape rocket heater ath bounce check smart steady today

  Buy

• YieldVector

  Jun 2, 2024

  $BDX passed money gains feels volume mode theta spicy soon flows clean crushing fire

  Buy

• AlphaVandal

  Feb 19, 2024

  $BDX on energy flows soon earnings theta passed hedges humming momentum humming trigger dripping risk whoa bull macro keeping

  Buy

• TheAlphaDagger

  Jan 20, 2024

  $BDX strong tbh trigger king rocket ath king wild keeping loud spike on staying

  Buy

• BuyTheDipBro

  Dec 28, 2023

  $BDX and and check now talking printing whispers heat oversold heating staying

  Buy

• ProfitVandal

  Nov 30, 2023

  $BDX theta lower tape whispers sentiment cat fading here diamond rip heavy

  Sell

• TradeMatrix

  Nov 27, 2023

  $BDX maybe queued tight diamond mooning charts bounce humming printing humming trend hard fast heat volume talking

  Buy